Affordable Access

Publisher Website

Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection.

Authors
Type
Published Article
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Publication Date
Volume
19
Issue
18
Pages
5227–5239
Identifiers
DOI: 10.1158/1078-0432.CCR-13-0489
PMID: 23935036
Source
Medline

Abstract

This study shows a discriminatory signature comprising mesothelin, FLT4, AGP, and CA-125 as potentially identifying those patients with EOC more likely to benefit from bevacizumab. These results require validation in further patient cohorts.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments